Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis …
Full XGN analysis →
Competitive advantage assessment
Key strengths
Expanding Operating MarginOperating margin trend is positive (score 0.60). Margin expansion confirms commercial leverage is building.
Durable Revenue GrowthRevenue growth trend is strong (score 0.83). Durable top-line expansion confirms the razor-and-blade flywheel is working.
Key risks
Weak Capital Return ProfileCapital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.
Weak FCF GenerationFCF margin quality lags peers (score 0.33). Below-peer FCF conversion is a MedTech quality warning.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Exagen Inc. ranks #40 of 62
scored companies in Diagnostics & Research by moat score — the top 65%.
The widest moat in the group is IDEXX Laboratories, Inc. (IDXX)
at 78/100.
Moat scores for companies ranked near XGN in Diagnostics & Research
How XGN scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 56
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 32
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 42
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 45
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 32
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 55
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Exagen Inc. (XGN) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #40 of 62 scored companies in Diagnostics & Research, the top 65%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (56/100) and its weakest is R&D Pipeline & Capital Returns (32/100).
How does Exagen Inc. compare with other Diagnostics & Research companies?
Exagen Inc. ranks #40 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Neuronetics, Inc. (STIM) at 45 just above it and Opko Health, Inc. (OPK) at 42 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.
Why is Exagen Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Exagen Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and XGN scores: Pricing Power & Consumable Moat (56), R&D Pipeline & Capital Returns (32), FCF Quality & Cash Conversion (42), Commercial Execution (45), Capital Structure & Resilience (32), Growth Durability (55). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.